A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Public ClinicalTrials.gov record NCT07114601. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)
Study identification
- NCT ID
- NCT07114601
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 421 participants
Conditions and interventions
Conditions
Interventions
- LY4257496 Drug
- LY4257529 Diagnostic Test
- Standard of Care Anticancer Therapies Drug
Drug · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2025
- Primary completion
- Mar 31, 2030
- Completion
- Mar 31, 2035
- Last update posted
- Apr 16, 2026
2025 – 2035
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Not yet recruiting |
| University of California, Los Angeles (UCLA) | Santa Monica | California | 90404 | Recruiting |
| Stanford University Medical Center | Stanford | California | 94305 | Recruiting |
| Biogenix Molecular, LLC | Miami | Florida | 33165 | Recruiting |
| Moffitt | Tampa | Florida | 33612 | Not yet recruiting |
| Emory University School of Medicine - Winship Cancer Institute | Atlanta | Georgia | 30322 | Not yet recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Not yet recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Not yet recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| BAMF Health Inc. | Grand Rapids | Michigan | 49503 | Recruiting |
| Washington University | St Louis | Missouri | 63110 | Recruiting |
| New York University (NYU) Langone Medical Center | New York | New York | 10016 | Not yet recruiting |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Texas Oncology - DFW (Sammons CC) | Dallas | Texas | 75246 | Not yet recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07114601, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07114601 live on ClinicalTrials.gov.